|
Re: Moderna says its vaccine is 94.5% affective in preventing COVID19 (Re: Abdullah Idrees)
|
Quote: مش نسبة الوفاة الحالية ٥٪؟ ودرجة نجاح الفاكسين ٩٤٪؟ طيب الفايدة شنو، فهمونا ياخوانا.. |
سلام عبدالله إدريس نسبة الوفاة 5% من عدد المصابين. درجة نجاح الفاكسين 94% بمعنى أنه يخفض معدل الإصابة بالمرض بنسبة 94% بين المطعمين إذا تعرضوا للفيروس. الأثر التراكمي للفاكسين في المجتمع أنه سيقلل حالات الإصابة وبالتالي يقلل عدد المرضى وتعرض أفراد المجتمع للفيروس. وبالتالي تنخفض مخاطر الإصابة بالفيروس في المجتمع إلى درجة قللة جداً وقد يقضي الفاكسين على الفيروس تماماً إذا تم تطعيم جزء كبير من المجتمع.
| |
|
|
|
|
|
|
Re: Moderna says its vaccine is 94.5% affective in preventing COVID19 (Re: Deng)
|
Pfizer 95% efficacy
Quote: (Reuters) - Pfizer Inc said on Wednesday that final results from the late-stage trial of its COVID-19 vaccine show it was 95% effective, adding it had the required two-months of safety data and would apply for emergency U.S. authorization within days.
The drugmaker said efficacy of the vaccine developed with German partner BioNTech SE was consistent across age and ethnicity demographics, and that there were no major side effects, a sign that the immunization could be employed broadly around the world.
Efficacy in adults over 65 years, who are at particular risk from the virus, was over 94%.
The final analysis comes just one week after initial results from the trial showed the vaccine was more than 90% effective.
Moderna Inc on Monday released preliminary data for its vaccine, showing similar effectiveness.
The better-than-expected data from the two vaccines, both developed with new technology known as messenger RNA (mRNA), have raised hopes for an end to a resurgent pandemic that has killed more than 1.3 million people globally and wreaked havoc upon economies and daily life.
However, while some groups such as healthcare workers will be prioritized in the United States for vaccinations this year, it will be months before large-scale rollouts begin.
Pfizer said on Wednesday there had been 170 cases of the disease in its trial of more 43,000 volunteers, of which 162 were observed in the placebo arm and 8 were in the vaccine group.
Ten people developed severe COVID-19, one of whom received the vaccine.
It also said the vaccine was well-tolerated and that side effects were mostly mild to moderate and cleared up quickly.
The only severe adverse event that affected more than 2% of those vaccinated was fatigue, which affected 3.7% of recipients after the second dose. Older adults tended to report fewer and milder solicited adverse events following vaccination.
The results come as the virus is running rampant in the United States, Europe and elsewhere, placing an enormous strain on healthcare systems with record numbers of new cases and hospitalizations.
The approach of winter in the northern hemisphere in tandem with the holiday season is expected to worsen case numbers as people spend more time indoors and get together for family gatherings.
"With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world," Pfizer CEO Albert Bourla said in a statement.
Pfizer and BioNTech also said they plan to submit the data to other regulatory agencies around the world as well as the United States. They also plan to submit data from the study to a peer-reviewed scientific journal.
Pfizer reiterated it expects to make as many as 50 million vaccine doses this year, enough to protect 25 million people, and then produce up to 1.3 billion doses in 2021.
Of the dozens of drugmakers and research groups racing to develop vaccines against COVID-19, the next data release will likely be from AstraZeneca Plc with the University of Oxford in November or December. Johnson and Johnson says it is on track to deliver data this year.
|
| |
|
|
|
|
|
|
Re: Moderna says its vaccine is 94.5% affective in preventing COVID19 (Re: Elhadi)
|
Pfizer Files for FDA Emergency Use Authorization of COVID Vaccine
شركة فايزر تقدمت للـ FDA ـ الهيئة المسئولة عن الأدوية والعقاقير في الولايات المتحدة ـ بطلب للحصول على تصريح استخدام لقاح كوفيد 19 بشكل طارئ
وستجتمع الـ FDA يوم العاشر من ديسمبر ( بعد حوالي عشرين يوم) للنظر في الطلب والتقرير ما إذا كان المصل آمن وفعال للحصول على التصريح اللازم
| |
|
|
|
|
|
|
Re: Moderna says its vaccine is 94.5% affective in preventing COVID19 (Re: Elhadi)
|
في خبر أيضاً مهم تم الإعلان عنه وهو أن هناك مائة مليون جرعة من مصل أو لقاح شركة Moderna جاهزة للتوزيع في الولايات المتحدة الامريكية..
في اللحظة التي تعلن فيها الـ FDA وهي الهيئة المسئولة عن منح الموافقة أو أجازة الأدوية والعقاقير، في اللحظة التي تعلن فيها عن أن المصل Safe and Effective
ستكون هذه المائة مليون جرعة لدى المستشفيات والهيئات الطبية والعلاجية لأعطائها للمواطنين.
| |
|
|
|
|
|
|
|